Development of monoclonal gammopathy precedes the development of Epstein‐Barr virus‐induced posttransplant lymphoproliferative disorder
Andrew D. Badley, Daniel F. Portela, Robin Patel, Robert A. Kyle, Thomas M. Habermann, John G. Strickler, Duane M. Ilstrup, Russell H. Wiesner, Piet De Groen, Randall C. Walker, Carlos V. Paya – 1 September 1996 – Epstein‐Barr virus (EBV)‐induced posttransplant lymphoproliferative disorder (PTLD) develops in 3% to 10% of solid organ transplant recipients with a resultant mortality of up to 70%. Unfortunately, there is no current marker which identifies patients who will develop this disease.